Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of “Hold” by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has been assigned a consensus recommendation of “Hold” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.60.

DRTS has been the subject of a number of analyst reports. LADENBURG THALM/SH SH raised their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, July 22nd. Barclays raised their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Finally, Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd.

Insider Transactions at Alpha Tau Medical

In related news, CFO Raphi Levy sold 2,270 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,262,520. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 112,270 shares of company stock worth $1,270,923 over the last three months. 39.50% of the stock is currently owned by company insiders.

Institutional Trading of Alpha Tau Medical

Large investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC purchased a new position in shares of Alpha Tau Medical during the fourth quarter worth about $48,000. Everhart Financial Group Inc. purchased a new stake in Alpha Tau Medical in the second quarter valued at approximately $126,000. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical in the third quarter valued at approximately $62,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical during the first quarter valued at approximately $132,000. Finally, Bank of America Corp DE lifted its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Stock Performance

Shares of DRTS opened at $11.79 on Friday. Alpha Tau Medical has a 52-week low of $2.87 and a 52-week high of $14.11. The stock’s 50-day simple moving average is $11.24 and its 200 day simple moving average is $8.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -17.60 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Research analysts forecast that Alpha Tau Medical will post -0.67 EPS for the current fiscal year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.